User menu

Tamoxifen and Ovarian Function

Bibliographic reference Berlière, Martine ; Duhoux, François ; Dalenc, Florence ; Baurain, Jean-François ; Delle Vigne, Laurence ; et. al. Tamoxifen and Ovarian Function. In: PLoS One, Vol. 8, no. 6, p. e66616 [1-6] (2013)
Permanent URL
  1. PM Rafdim, Cancer Res, 48, 1026 (1988)
  2. Dellapasqua Silvia, Colleoni Marco, Gelber Richard D., Goldhirsch Aron, Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer, 10.1200/jco.2005.11.050
  3. A Gonzalez Martin, 10, 1045 (2010)
  4. Lancet, 339(1), 71 (1992)
  5. Lancet, 365(9472), 1687 (2005)
  6. Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93, 10.1200/jco.2005.03.0783
  7. Ortmann O., Pagani O., Jones A., Maass N., Noss D., Rugo H., van de Velde C., Aapro Matti, Coleman R., Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel, 10.1016/j.ctrv.2010.05.005
  8. Guidelines of the NCCN (2011) Definition of menopause. Available:
  9. Burger H.G., Hale G.E., Robertson D.M., Dennerstein L., A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project, 10.1093/humupd/dmm020
  10. J Cuzick, Lancet, 369(9574), 1711 (2007)
  11. Walshe Janice M., Denduluri Neelima, Swain Sandra M., Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer, 10.1200/jco.2006.07.2793
  12. Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, et al.. (2011) Menstrual history and quality of life outcomes in women with node positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (
  13. Petrek Jeanne A., Naughton Michelle J., Case L. Douglas, Paskett Electra D., Naftalis Elizabeth Z., Singletary S. Eva, Sukumvanich Paniti, Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study, 10.1200/jco.2005.03.3969
  14. Shapiro Charles L., Recht Abram, Side Effects of Adjuvant Treatment of Breast Cancer, 10.1056/nejm200106283442607
  15. A Manni, Cancer Treat Rep, 64, 779 (1980)
  16. Jordan V. C., Fritz N. F., Langan-Fahey S., Thompson M., Tormey D. C., Alteration of Endocrine Parameters in Premenopausal Women With Breast Cancer During Long-Term Adjuvant Therapy With Tamoxifen as the Single Agent, 10.1093/jnci/83.20.1488
  17. VC Jordan, Cancer Res, 47, 624 (1987)
  18. Mourits Marian J.E., de Vries Elisabeth G.E., ten Hoor Klaske A., van der Zee Ate G.J., Willemse Pax H.B., Beware of Amenorrhea During Tamoxifen: It May Be a Wolf in Sheep's Clothing, 10.1200/jco.2007.11.1633
  19. Speroff L, Glass RH, Kase NG (1999) Clinical gynaecologic endocrinology and infertility. Ed. Philadelphia PA, Lippincott, Williams and Wilkins.
  20. Bath L.E., Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound, 10.1093/humrep/deg473
  21. Su H. Irene, Sammel Mary D., Green Jamie, Velders Luke, Stankiewicz Corrie, Matro Jennifer, Freeman Ellen W., Gracia Clarisa R., DeMichele Angela, Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors, 10.1002/cncr.24746
  22. Sakurai Kenichi, Enomoto Katsuhisa, Amano Sadao, Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer, 10.1007/s00432-010-0894-8
  23. Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane R C, Ahmad I, Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects, 10.1038/clpt.2010.196
  24. Goetz Matthew P., Rae James M., Suman Vera J., Safgren Stephanie L., Ames Matthew M., Visscher Daniel W., Reynolds Carol, Couch Fergus J., Lingle Wilma L., Flockhart David A., Desta Zeruesenay, Perez Edith A., Ingle James N., Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes, 10.1200/jco.2005.03.3266
  25. MS Singh, Breast, 20(2), 111 (2005)
  26. Stebbing Justin, Stearns Vered, Davidson Nancy E, Role ofCYP2D6testing in selection of endocrine therapy for breast cancer, 10.2217/14622416.8.1.1